Whitepaper
21 Sep 2023

CB21 Pharma, the spin-off sister company to CBDepot, successfully extends EU GMP certification to broaden its cannabis-derived active pharmaceutical ingredients (API) portfolio.

DOCX 741 kB

CB21 Pharma, a leading Czech-based pharmaceutical company specializing in producing cannabinoid ingredients and medical devices, has successfully extended its EU Good Manufacturing Practice (GMP) certification under certificate # sukls105303/2023. This achievement allows CB21 Pharma, the spin-off sister company to pioneering CBDepot, to continue manufacturing Active Pharmaceutical Ingredients (APIs) such as Cannabidiol (CBD), from initial extraction to the production of full spectrum distilled and standardized extracts from medicinal cannabis, marketed as Cannabis Extractum Raffinatum and Cannabis Extractum Normatum. 

Content provided by our supplier

CBDepot

  • SK
  • 2017
    On CPHI since
  • 2
    Certificates
  • 25 - 49
    Employees
Company types
Distributor/Import Export

Other Content from CBDepot (1)